Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov-Dec;34(6):3675-3679.
doi: 10.21873/invivo.12215.

Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers

Anand Sharma  1 , Deshveer S Babra  2 , Priya V Joshi  2 , Marcia Hall  2 , Andrew Gogbashian  3 , Nikhil Vasdev  4 , Magdalene Joseph  2 , Amir Yazdan  2 , Edward Kanfer  5
Affiliations

Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers

Anand Sharma et al. In Vivo. 2020 Nov-Dec.

Abstract

Background/aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.

Patients and methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes.

Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients hadMedian survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance.

Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.

Keywords: Relapsed germ cell cancer; high dose chemotherapy; stem cell transplant; survival.

PubMed Disclaimer

Conflict of interest statement

The Authors have no conflicts of interest to declare regarding this study.

Figures

Figure 1
Figure 1. Kaplan-Meier curve demonstrating survival post-high dose chemotherapy and stem cell transplant
See this image and copyright information in PMC

References

    1. Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D. High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells. 2015;7(11):1222–1232. doi: 10.4252/wjsc.v7.i11.1222. - DOI - PMC - PubMed
    1. Sharma A, Alifrangis C, Milic M, Hall M, Vasdev N, Wilson P, Gogbashian A, Hrouda D, Berney D, Shamash J. Somatic transformation in metastatic testicular germ cell tumours – a different disease entity. Anticancer Res. 2019;39(9):4911–4916. doi: 10.21873/anticanres.13678. - DOI - PubMed
    1. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559–2563. doi: 10.1200/JCO.1997.15.7.2559. - DOI - PubMed
    1. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favourable prognosis germ-cell tumors: The Indian University experience. J Clin Oncol. 1998;16(2):702–706. doi: 10.1200/JCO/1998.16.2.702. - DOI - PubMed
    1. Adra N, Abonour R. High-dose chemotherapy and autologous stem cell transplant. Urol Clin North Am. 2019;46(3):439–448. doi: 10.1016/j.ucl.2019.07.007. - DOI - PubMed

LinkOut - more resources